BR9911861A - Inibidores de farnesil proteìna transferase com as propriedades radiossensibilizadoras in vivo - Google Patents

Inibidores de farnesil proteìna transferase com as propriedades radiossensibilizadoras in vivo

Info

Publication number
BR9911861A
BR9911861A BR9911861-0A BR9911861A BR9911861A BR 9911861 A BR9911861 A BR 9911861A BR 9911861 A BR9911861 A BR 9911861A BR 9911861 A BR9911861 A BR 9911861A
Authority
BR
Brazil
Prior art keywords
vivo
protein transferase
transferase inhibitors
farnesyl protein
radiosensitizing properties
Prior art date
Application number
BR9911861-0A
Other languages
English (en)
Inventor
Robert Franciscus Van Ginckel
Win Joanna Floren
David William End
Walter Boudewijn Leopo Wouters
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR9911861A publication Critical patent/BR9911861A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Patente de Invenção: <B>"INIBIDORES DE FARNESIL PROTEìNA TRANSFERASE COM AS PROPRIEDADES RADIOSSENSIBILIZADORAS IN VIVO"<D>. A presente invenção refere-se à descoberta de que os inibidores de farnesil proteína transferase têm propriedades radiossensibilizadoras o que os torna úteis para a preparação de uma composição farmacêutica para administração antes, durante ou após a irradiação de um tumor para tratamento de câncer in vivo.
BR9911861-0A 1998-07-06 1999-06-30 Inibidores de farnesil proteìna transferase com as propriedades radiossensibilizadoras in vivo BR9911861A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98202257 1998-07-06
EP98204330 1998-12-18
PCT/EP1999/004545 WO2000001411A1 (en) 1998-07-06 1999-06-30 Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties

Publications (1)

Publication Number Publication Date
BR9911861A true BR9911861A (pt) 2001-03-20

Family

ID=26150503

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9911861-0A BR9911861A (pt) 1998-07-06 1999-06-30 Inibidores de farnesil proteìna transferase com as propriedades radiossensibilizadoras in vivo

Country Status (31)

Country Link
US (1) US6545020B1 (pt)
EP (1) EP1094839B1 (pt)
JP (1) JP4530537B2 (pt)
KR (1) KR100591603B1 (pt)
CN (1) CN1152716C (pt)
AP (1) AP1599A (pt)
AT (1) ATE238811T1 (pt)
AU (1) AU762423B2 (pt)
BG (1) BG64941B1 (pt)
BR (1) BR9911861A (pt)
CA (1) CA2336624C (pt)
CZ (1) CZ300968B6 (pt)
DE (1) DE69907461T2 (pt)
DK (1) DK1094839T3 (pt)
EA (1) EA003877B1 (pt)
EE (1) EE04582B1 (pt)
ES (1) ES2199579T3 (pt)
HK (1) HK1034451A1 (pt)
HR (1) HRP20000903A2 (pt)
HU (1) HU229076B1 (pt)
ID (1) ID26987A (pt)
IL (2) IL140721A0 (pt)
MY (1) MY126519A (pt)
NO (1) NO328178B1 (pt)
PL (1) PL193464B1 (pt)
PT (1) PT1094839E (pt)
SI (1) SI1094839T1 (pt)
SK (1) SK284723B6 (pt)
TR (1) TR200003879T2 (pt)
TW (1) TW586937B (pt)
WO (1) WO2000001411A1 (pt)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1152716C (zh) 1998-07-06 2004-06-09 詹森药业有限公司 具体内射线感受性的法呢基蛋白质转移酶抑制剂
BR9911869A (pt) 1998-07-06 2001-03-27 Janssen Pharmaceutica Nv Inibidores da transferase da proteìna farnesil para o tratamento das artropatias
DE60118889T2 (de) * 2000-02-04 2006-11-30 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs
JO2361B1 (en) * 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
EP1322635B1 (en) 2000-09-25 2006-03-22 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
US7196094B2 (en) 2000-09-25 2007-03-27 Janssen Pharmaceutica, N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
JP4974437B2 (ja) 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する６−［（置換フェニル）メチル］−キノリンおよびキナゾリン誘導体
EP1322644A1 (en) 2000-09-25 2003-07-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
ES2328225T3 (es) 2000-11-21 2009-11-11 Janssen Pharmaceutica Nv Derivados benzoheterociclicos inhibidores de la farnesil-transferasa.
ATE319704T1 (de) 2000-12-27 2006-03-15 Janssen Pharmaceutica Nv Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
DE60119383T2 (de) * 2000-12-27 2007-04-19 Janssen Pharmaceutica N.V. Farnesyltransferasehemmende 4-heterocyclylchinolin- und chinazolinderivate
US6713462B2 (en) 2001-06-21 2004-03-30 Ariad Pharmaceuticals, Inc. Quinolinones and uses thereof
US7408063B2 (en) 2001-12-19 2008-08-05 Janssen Pharmaceutica, N.V. 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
US7241777B2 (en) 2002-03-22 2007-07-10 Janssen Pharmaceutica N.V. Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
DE60307616T2 (de) 2002-04-15 2007-10-04 Janssen Pharmaceutica N.V. Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
CA2546300C (en) * 2003-11-20 2012-10-02 Janssen Pharmaceutica N.V. 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
CA2546727C (en) 2003-11-20 2012-10-02 Children's Hospital Medical Center Gtpase inhibitors and methods of use
US20050288298A1 (en) * 2004-03-18 2005-12-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
EP1744751A4 (en) * 2004-03-18 2010-03-10 Brigham & Womens Hospital TREATMENT OF SYNUCLEINOPATHIES
US20050272068A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. UCH-L1 expression and cancer therapy
US20060106060A1 (en) * 2004-03-18 2006-05-18 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
CA2617056A1 (en) 2005-07-29 2007-02-08 Children's Hospital Medical Center Gtpase inhibitors and methods of use and crystal structure of rac-1 gtpase
CA2634598A1 (en) 2005-12-23 2007-07-05 Link Medicine Corporation Treatment of synucleinopathies
BRPI0811781A2 (pt) * 2007-05-23 2014-11-11 Allergan Inc Compostos de ((fenil) imidazolil)metilquinolinila terapêuticos.
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
ATE555384T1 (de) 2008-06-26 2012-05-15 Spherotec Gmbh Verfahren zum testen der reaktion von zellen auf die einwirkung von therapeutika
CA2743717A1 (en) * 2008-11-13 2010-05-20 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
WO2013166043A1 (en) 2012-05-02 2013-11-07 Children's Hospital Medical Center Rejuvenation of precursor cells
WO2014062655A1 (en) 2012-10-16 2014-04-24 Janssen Pharmaceutica Nv HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt
AU2013331505A1 (en) 2012-10-16 2015-04-30 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ROR-gamma-t
CA2888210C (en) 2012-10-16 2021-02-09 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of ror-gamma-t
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
EP3057422B1 (en) 2013-10-15 2019-05-15 Janssen Pharmaceutica NV Quinolinyl modulators of ror(gamma)t
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
JP6423423B2 (ja) 2013-10-15 2018-11-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｒｏｒγｔのアルキル結合キノリニルモジュレーター
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
CA2985123C (en) 2015-08-17 2021-04-13 Antonio Gualberto Methods of treating cancer patients with farnesyltransferase inhibitors
WO2017184968A1 (en) 2016-04-22 2017-10-26 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
MY190861A (en) 2016-11-03 2022-05-12 Kura Oncology Inc Farnesyltransferase inhibitors for use in methods of treating cancer
US9956215B1 (en) 2017-02-21 2018-05-01 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
MX2019009821A (es) 2017-02-21 2019-12-02 Kura Oncology Inc Metodos para tratar cancer con inhibidores de farnesiltransferasa.
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
BR112020002591A2 (pt) 2017-08-07 2020-07-28 Kura Oncology, Inc. método para o tratamento de câncer
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
CN113286591A (zh) 2018-11-01 2021-08-20 库拉肿瘤学公司 用法尼基转移酶抑制剂治疗癌症的方法
US20220142983A1 (en) 2019-03-01 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2020190604A1 (en) 2019-03-15 2020-09-24 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
TW202043487A (zh) 2019-03-29 2020-12-01 美商庫拉腫瘤技術股份有限公司 以法尼基轉移酶(farnesyltransferase)抑制劑治療鱗狀細胞癌之方法
US20220168296A1 (en) 2019-04-01 2022-06-02 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2020223583A1 (en) 2019-05-02 2020-11-05 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141851A (en) * 1990-04-18 1992-08-25 Board Of Regents, The University Of Texas System Isolated farnesyl protein transferase enzyme
US6083917A (en) * 1990-04-18 2000-07-04 Board Of Regents, The University Of Texas System Methods and compositions for the identification, characterization and inhibition of farnesyltransferase
US5602184A (en) 1993-03-03 1997-02-11 The United States Of America As Represented By Department Of Health And Human Services Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
DE69620445T2 (de) * 1995-12-08 2002-12-12 Janssen Pharmaceutica N.V., Beerse (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
EP0910385A4 (en) * 1996-04-15 1999-12-22 Univ Pennsylvania SENSITIZATION OF CELLS FOR RADIATION AND CHEMOTHERAPY
JP2000514456A (ja) * 1996-07-15 2000-10-31 ブリストル―マイヤーズ・スクイブ・カンパニー ファルネシルプロテイントランスフェラーゼのチアジオキソベンゾジアゼピン阻害剤
TW591030B (en) 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
CN1152716C (zh) 1998-07-06 2004-06-09 詹森药业有限公司 具体内射线感受性的法呢基蛋白质转移酶抑制剂
CN1340051A (zh) * 1999-02-11 2002-03-13 辉瑞产品公司 可用作抗癌剂的杂芳基取代的喹啉－2－酮衍生物

Also Published As

Publication number Publication date
HK1034451A1 (en) 2001-10-26
PL193464B1 (pl) 2007-02-28
DE69907461D1 (de) 2003-06-05
PL347979A1 (en) 2002-05-06
HRP20000903A2 (en) 2001-12-31
JP4530537B2 (ja) 2010-08-25
AU4780599A (en) 2000-01-24
DE69907461T2 (de) 2004-02-19
IL140721A0 (en) 2002-02-10
JP2002519389A (ja) 2002-07-02
ES2199579T3 (es) 2004-02-16
SK284723B6 (sk) 2005-10-06
KR20010052770A (ko) 2001-06-25
HU229076B1 (en) 2013-07-29
HUP0103689A3 (en) 2003-01-28
AP1599A (en) 2006-04-27
EA200100111A1 (ru) 2001-06-25
ID26987A (id) 2001-02-22
CZ300968B6 (cs) 2009-09-30
EE200000794A (et) 2002-06-17
CA2336624A1 (en) 2000-01-13
CZ20004777A3 (en) 2001-05-16
EP1094839B1 (en) 2003-05-02
EA003877B1 (ru) 2003-10-30
CA2336624C (en) 2008-10-21
CN1311692A (zh) 2001-09-05
TR200003879T2 (tr) 2007-01-22
HUP0103689A2 (hu) 2002-02-28
BG105108A (en) 2001-11-30
SI1094839T1 (en) 2003-12-31
MY126519A (en) 2006-10-31
EE04582B1 (et) 2006-02-15
DK1094839T3 (da) 2003-08-18
BG64941B1 (bg) 2006-10-31
TW586937B (en) 2004-05-11
WO2000001411A1 (en) 2000-01-13
NO20010082D0 (no) 2001-01-05
IL140721A (en) 2008-11-26
KR100591603B1 (ko) 2006-06-20
PT1094839E (pt) 2003-09-30
EP1094839A1 (en) 2001-05-02
US6545020B1 (en) 2003-04-08
SK19862000A3 (sk) 2001-12-03
AU762423B2 (en) 2003-06-26
NO20010082L (no) 2001-01-05
ATE238811T1 (de) 2003-05-15
AP2001002057A0 (en) 2001-03-31
CN1152716C (zh) 2004-06-09
NO328178B1 (no) 2009-12-28

Similar Documents

Publication Publication Date Title
BR9911861A (pt) Inibidores de farnesil proteìna transferase com as propriedades radiossensibilizadoras in vivo
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
BR9807824A (pt) Derivados de n-hidróxi-beta-sulfonil-propionamida e seu uso como inibidores de metaloproteinases de matriz
BR0000003A (pt) Azalidas e métodos de preparação das mesmas
BR0109704A (pt) Método de tratamento usando conjugados de imunógeno ligando
BR9815442A (pt) Liberação terapêutica dirigida de compostos de vitamina d
BR9908030A (pt) Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado
BR0009670A (pt) Métodos de induzir morte de células de câncer e regressão de tumor
CY1105477T1 (el) Αναστολεις τρανσφepασης φαρνεσυλ πρωτεϊνης για τη θepαπευτικη αντιμετωπιση του καρκινου του μαστου
BR0208373A (pt) Inibidores da tirosina cinase
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
BR9915210A (pt) N-aril-amidas de ácido antranìlico-e ácido tioantranìlico
MXPA03006771A (es) Anticuerpos modificados y metodos de uso.
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
RS41104A (en) Sulphonamide derivatives, the preparation thereof and the application of same as medicaments
BR0207487A (pt) Método de tratamento de tumores em mamìferos e uso de compostos de epotilona
BRPI0414215A (pt) tienopirazóis
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
PT1268472E (pt) Inibidores 3-aminopirazolicos de cinases dependentes da ciclina
BR0009608A (pt) Compostos para imunoterapia e diagnóstico de câncer de mama e métodos para sua utilização
CY1105179T1 (el) Φαρμακα για την ανοσοθepαπεια κακοηθων ογκων
BR0015597A (pt) Uso de anticorpos como vacinas
BRPI0418223A (pt) composição que compreende um extrato aquoso de folhas de vinha vermelha e um agente de melhoria da circulação sangüìnea para o tratamento de insuficiências venosas crÈnicas

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]